Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
Holdings in Q2 2022
Holdings as of Jun 30, 2022, filed Aug 15, 2022. Long positions only; changes compare share counts with Q1 2022.
- Positions
- 24
- −3 vs. Q1 2022
- Portfolio value
- $473.0M
- +$25.3M (+5.6%) vs. Q1 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| IVAInventiva S.A. | ADS | 175,500 | $995.0K | 0.2% | −87,158−33.2% | Reduced | History |
| TNYATenaya Therapeutics, Inc. | COM | 357,699 | $2.01M | 0.4% | −156,231−30.4% | Reduced | History |
| BCLS Acquisition CorpG0904B105 | COM CL A | 250,000 | $2.48M | 0.5% | 00.0% | Unchanged | – |
| KALVKalVista Pharmaceuticals, Inc. | COM | 312,553 | $3.08M | 0.7% | 00.0% | Unchanged | History |
| IMUXImmunic, Inc. | COM | 893,013 | $3.10M | 0.7% | 00.0% | Unchanged | History |
| RZLTRezolute, Inc. | COM NEW | 1,210,000 | $3.91M | 0.8% | +1,210,000 | New | History |
| CELCCelcuity Inc. | COM | 920,464 | $8.38M | 1.8% | 00.0% | Unchanged | History |
| KPTIKaryopharm Therapeutics Inc. | COM | 1,935,609 | $8.73M | 1.8% | −1,625,443−45.6% | Reduced | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 312,533 | $11.0M | 2.3% | +312,533 | New | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 13,049,079 | $11.5M | 2.4% | +2,951,850+29.2% | Added | History |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 739,661 | $13.2M | 2.8% | +739,661 | New | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 538,812 | $14.5M | 3.1% | +297,613+123.4% | Added | History |
| STSASatsuma Pharmaceuticals, Inc. | COM | 3,711,286 | $15.4M | 3.2% | 00.0% | Unchanged | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 5,738,500 | $16.9M | 3.6% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,638,609 | $19.0M | 4.0% | +687,270+72.2% | Added | History |
| TCDATricida, Inc. | COM | 2,028,453 | $19.6M | 4.2% | +283,883+16.3% | Added | History |
| ISEEIVERIC bio, Inc. | COM | 2,409,961 | $23.2M | 4.9% | +195,000+8.8% | Added | History |
| KURAKura Oncology, Inc. | COM | 1,826,491 | $33.5M | 7.1% | +1,049,977+135.2% | Added | History |
| ACRSAclaris Therapeutics, Inc. | COM | 2,410,622 | $33.7M | 7.1% | +95,974+4.1% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 893,646 | $35.1M | 7.4% | +38,994+4.6% | Added | History |
| Bellus Health Inc New07987C204 | COM NEW | 4,479,784 | $41.4M | 8.8% | −1,157,846−20.5% | Reduced | – |
| COGTCogent Biosciences, Inc. | COM | 4,944,708 | $44.6M | 9.4% | +1,443,940+41.2% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 1,594,932 | $48.5M | 10.3% | +392,319+32.6% | Added | History |
| MRUSMerus N.V. | COM | 2,615,762 | $59.2M | 12.5% | +799,341+44.0% | Added | History |
Sold out since Q1 2022 (6)
Positions held at the end of Q1 2022 that are gone from this filing.
| Security | Class | Shares in Q1 2022 | Value in Q1 2022 | % of portfolio in Q1 2022 | History |
|---|---|---|---|---|---|
| CCCCC4 Therapeutics, Inc. | COM STK | 481,094 | $11.7M | 2.6% | History |
| PTGXProtagonist Therapeutics, Inc | COM | 331,886 | $7.86M | 1.8% | History |
| GNCAGenocea Biosciences, Inc. | COM NEW | 3,079,756 | $3.85M | 0.9% | History |
| DYNDyne Therapeutics, Inc. | COM | 305,125 | $2.94M | 0.7% | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 125,000 | $2.60M | 0.6% | History |
| MREOMereo BioPharma Group plc | SPON ADS | 1,954,970 | $2.19M | 0.5% | History |